Search
Statistics
We have 222 registered usersThe newest registered user is raheelmemon
Our users have posted a total of 1140 messages in 613 subjects
If you are seeing this, you have attempted to link to the UpToDate widget but are experiencing a problem. Please visit UpToDate for more information.
Caution on Zyprexa in Adolescents & Elderly
FORUM FOR PSYCHIATRY RESIDENTS :: Psychiatry :: Psychiatry-Neurology-Psychology discussion :: Psychiatry Video Lectures
Page 1 of 1
Caution on Zyprexa in Adolescents & Elderly
Caution on Zyprexa in Adolescents
The FDA is recommending that healthcare professionals use caution when considering Zyprexa (olanzapine) for treating adolescents 13 to 17 years old for schizophrenia and bipolar disorder.
Physicians, patients and caregivers should understand that adolescents may experience weight gain and hyperlipidemia with Zyprexa. In fact, they have a greater risk of these effects than adults. They are likely to gain more weight than adults and have greater increases in total cholesterol, LDL cholesterol, triglycerides, prolactin, and hepatic transaminase levels. Adolescents are also more likely to experience sedation than adults. Clinicians should take these effects into account when deciding on antipsychotic medications for adolescents, and they may want to consider trying other drugs first.
If Zyprexa is prescribed for adolescents, it should be part of a comprehensive treatment program that often includes psychological, educational and social components. It is also important to note that Zyprexa has not been approved for patients under the age of 13.
Caution on Zyprexa in Elderly
Now a warning about the drug ZYPREXA (olanzapine), made by Eli Lilly and company.
ZYPREXA is used to treat schizophrenia and bipolar disorder.
The WARNINGS section of the drug's label now describes cerebrovascular adverse events. These have occurred in elderly patients being treated for dementia-related psychosis in clinical trials. These events, some of them fatal, have included stroke and TIAs. The labeling reminds practitioners that ZYPREXA has not been approved for the treatment of patients with dementia-related psychosis.
The FDA is recommending that healthcare professionals use caution when considering Zyprexa (olanzapine) for treating adolescents 13 to 17 years old for schizophrenia and bipolar disorder.
Physicians, patients and caregivers should understand that adolescents may experience weight gain and hyperlipidemia with Zyprexa. In fact, they have a greater risk of these effects than adults. They are likely to gain more weight than adults and have greater increases in total cholesterol, LDL cholesterol, triglycerides, prolactin, and hepatic transaminase levels. Adolescents are also more likely to experience sedation than adults. Clinicians should take these effects into account when deciding on antipsychotic medications for adolescents, and they may want to consider trying other drugs first.
If Zyprexa is prescribed for adolescents, it should be part of a comprehensive treatment program that often includes psychological, educational and social components. It is also important to note that Zyprexa has not been approved for patients under the age of 13.
Caution on Zyprexa in Elderly
Now a warning about the drug ZYPREXA (olanzapine), made by Eli Lilly and company.
ZYPREXA is used to treat schizophrenia and bipolar disorder.
The WARNINGS section of the drug's label now describes cerebrovascular adverse events. These have occurred in elderly patients being treated for dementia-related psychosis in clinical trials. These events, some of them fatal, have included stroke and TIAs. The labeling reminds practitioners that ZYPREXA has not been approved for the treatment of patients with dementia-related psychosis.
Similar topics
» Antioxidants for Alzheimer Disease: Caution Raised
» Q. Which Antipsychotic is Preferred for Management of Psychosis in Elderly with Parkinson's Disease?
» Cortical Abnormalities in Adults & Adolescents with MDD
» Prevalence, Persistence, and Sociodemographic Correlates of DSM-IV Disorders in Adolescents
» Which antidepressant is best option for major depressive disorder in children and adolescents
» Q. Which Antipsychotic is Preferred for Management of Psychosis in Elderly with Parkinson's Disease?
» Cortical Abnormalities in Adults & Adolescents with MDD
» Prevalence, Persistence, and Sociodemographic Correlates of DSM-IV Disorders in Adolescents
» Which antidepressant is best option for major depressive disorder in children and adolescents
FORUM FOR PSYCHIATRY RESIDENTS :: Psychiatry :: Psychiatry-Neurology-Psychology discussion :: Psychiatry Video Lectures
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum
Sat Sep 10, 2016 1:45 pm by Admin
» L-Methylfolate: Who Will benefit
Sat Sep 03, 2016 3:00 pm by Admin
» Vitamins & Supplements in Clinical Practice.
Sun Aug 21, 2016 12:27 pm by Admin
» Imaging Biomarkers for Outcomes in Mild TBI
Fri Jul 22, 2016 12:37 pm by Admin
» Q.5 Clozapine Neutopenia
Mon Jul 11, 2016 8:43 pm by Admin
» Treating Disorders!
Mon Jul 04, 2016 1:52 am by troymackys
» Cortical Abnormalities in Adults & Adolescents with MDD
Sun Jul 03, 2016 12:59 pm by Admin
» Efficacy of Antipsychotics in Pediatric Acute Mania
Wed Jun 22, 2016 8:46 pm by Admin
» Obsessive Compulsive Disorder in Adults: Which Treatment is Better?
Tue Jun 21, 2016 9:34 pm by Admin